CA2522060C - Fragments of fluorescent proteins for protein fragment complementation assays - Google Patents

Fragments of fluorescent proteins for protein fragment complementation assays Download PDF

Info

Publication number
CA2522060C
CA2522060C CA2522060A CA2522060A CA2522060C CA 2522060 C CA2522060 C CA 2522060C CA 2522060 A CA2522060 A CA 2522060A CA 2522060 A CA2522060 A CA 2522060A CA 2522060 C CA2522060 C CA 2522060C
Authority
CA
Canada
Prior art keywords
aag
lys
leu
ctg
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2522060A
Other languages
English (en)
French (fr)
Other versions
CA2522060A1 (en
Inventor
Stephen William Watson Michnick
Marnie L. Macdonald
Jane Lamerdin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Odyssey Pharmaceuticals Inc
Original Assignee
Odyssey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Odyssey Pharmaceuticals Inc filed Critical Odyssey Pharmaceuticals Inc
Publication of CA2522060A1 publication Critical patent/CA2522060A1/en
Application granted granted Critical
Publication of CA2522060C publication Critical patent/CA2522060C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43595—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from coelenteratae, e.g. medusae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2522060A 2003-04-09 2004-04-09 Fragments of fluorescent proteins for protein fragment complementation assays Expired - Fee Related CA2522060C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46113303P 2003-04-09 2003-04-09
US60/461,133 2003-04-09
US10/724,178 US7166424B2 (en) 1998-02-02 2003-12-01 Fragments of fluorescent proteins for protein fragment complementation assays
US10/724,178 2003-12-01
PCT/US2004/010982 WO2004092336A2 (en) 1998-02-02 2004-04-09 Fragments of fluorescent proteins for protein fragment complementation assays

Publications (2)

Publication Number Publication Date
CA2522060A1 CA2522060A1 (en) 2004-10-28
CA2522060C true CA2522060C (en) 2013-10-01

Family

ID=35385090

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2522060A Expired - Fee Related CA2522060C (en) 2003-04-09 2004-04-09 Fragments of fluorescent proteins for protein fragment complementation assays

Country Status (6)

Country Link
US (2) US7166424B2 (https=)
EP (2) EP2317318A1 (https=)
JP (2) JP2006524244A (https=)
AU (2) AU2004230600A1 (https=)
CA (1) CA2522060C (https=)
WO (1) WO2004092336A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897017B1 (en) * 1997-01-31 2005-05-24 Odyssey Thera Inc. Vivo library-versus-library selection of optimized protein-protein interactions
US20020064769A1 (en) * 2000-10-05 2002-05-30 Watson Michnick Stephen William Dynamic visualization of expressed gene networks in living cells
US7062219B2 (en) * 1997-01-31 2006-06-13 Odyssey Thera Inc. Protein fragment complementation assays for high-throughput and high-content screening
US20050221280A1 (en) * 1998-02-02 2005-10-06 Odyssey Thera, Inc. Protein-protein interactions for pharmacological profiling
JP3829252B2 (ja) * 2001-06-08 2006-10-04 独立行政法人理化学研究所 蛍光蛋白質
US20040241636A1 (en) * 2003-05-30 2004-12-02 Michnick Stephen William Watson Monitoring gene silencing and annotating gene function in living cells
US20070224615A1 (en) * 2003-07-09 2007-09-27 Invitrogen Corporation Methods for assaying protein-protein interactions
US7488583B2 (en) * 2003-09-25 2009-02-10 Odyssey Thera, Inc. Fragment complementation assays for G-protein-coupled receptors and their signaling pathways
GB0327143D0 (en) * 2003-11-21 2003-12-24 Univ Belfast Assay
WO2006017279A2 (en) * 2004-07-12 2006-02-16 Board Of Regents, The University Of Texas System Methods and compositions related to identifying protein-protein interactions
US20060094059A1 (en) * 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
US20060094682A1 (en) 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
AU2005314231A1 (en) * 2004-12-04 2006-06-15 The Regents Of The University Of California Protein subcellular localization assays using split fluorescent proteins
CA2606876C (en) * 2005-05-03 2018-07-10 Georgia State University Research Foundation, Inc. Fluorescent proteins and uses thereof
US20090149338A1 (en) * 2005-09-30 2009-06-11 Hughes Thomas E System for detecting protein-protein interactions
US20090029370A1 (en) * 2005-10-27 2009-01-29 Trustees Of Boston University Real time nucleic acid detection in vivo using protein complementation
EP1948825A2 (en) * 2005-10-27 2008-07-30 The Trustees Of Boston University Activated split-polypeptides and methods for their production and use
WO2008018905A2 (en) * 2006-01-17 2008-02-14 Cellumen, Inc. Method for predicting biological systems responses
EP1847604A1 (en) 2006-04-19 2007-10-24 Millegen Intracellular method for selecting a peptide or polypeptide which binds to a bait peptide or polypeptide
CN101484806A (zh) 2006-05-17 2009-07-15 协乐民公司 一种对组织进行自动分析的方法
WO2008060483A2 (en) * 2006-11-10 2008-05-22 Cellumen, Inc. Protein-protein interaction biosensors and methods of use thereof
CA2704226A1 (en) * 2007-11-01 2009-05-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Cell-free methods for detecting protein-ligand interctions
US20100081632A1 (en) * 2008-03-06 2010-04-01 Odyssey Thera, Inc. High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
BR112013004294A2 (pt) 2010-08-24 2016-05-31 Safewhite Llc métodos e materiais para fornecimento de dentes com uma aparência branca.
ES2739623T3 (es) 2011-03-17 2020-02-03 Cernostics Inc Sistemas y composiciones para diagnosticar el esófago de Barrett y métodos para usarlos
DK3094974T3 (da) 2014-01-14 2019-05-27 Asedasciences Ag Identifikation af funktionelle cellers tilstande
CA2851568A1 (en) 2014-05-09 2015-11-09 The Governors Of The University Of Alberta Drug discovery and protein-protein interaction assay using flourescent protein exchange
KR101751917B1 (ko) * 2016-02-02 2017-06-28 기초과학연구원 가역적으로 활성화 가능한 항체 유사체 및 그의 용도
CN108267595A (zh) * 2017-11-27 2018-07-10 南京天纵易康生物科技股份有限公司 一种基于双分子荧光互补技术的Myo检测试剂盒、制备及使用方法
CN111718417B (zh) * 2019-03-19 2022-10-14 宁波鲲鹏生物科技有限公司 含有荧光蛋白片段的融合蛋白及其用途
EP4554964A1 (en) * 2022-07-11 2025-05-21 Cornell University Chemically stable fluorescent proteins for advanced microscopy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7062219B2 (en) * 1997-01-31 2006-06-13 Odyssey Thera Inc. Protein fragment complementation assays for high-throughput and high-content screening
US6294330B1 (en) * 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
CA2196496A1 (en) * 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
EP1283846A4 (en) * 2000-05-12 2005-06-01 Univ Yale METHODS FOR DETECTING INTERACTIONS BETWEEN PROTEINS, PEPTIDES OR THEIR LIBRARIES USING FUSION PROTEINS
JP2006506950A (ja) * 2002-04-19 2006-03-02 バイオイメージ・アクティーゼルスカブ ２つの緑色蛍光タンパク質断片およびタンパク質−タンパク質の相互作用を検出するための方法におけるこれらの使用
AU2003226955A1 (en) * 2002-04-19 2003-11-03 Bioimage A/S Translocation dependent complementation for drug screening

Also Published As

Publication number Publication date
JP2006524244A (ja) 2006-10-26
WO2004092336A2 (en) 2004-10-28
AU2004230600A1 (en) 2004-10-28
US20040137528A1 (en) 2004-07-15
JP2011182796A (ja) 2011-09-22
WO2004092336A3 (en) 2005-06-09
US7166424B2 (en) 2007-01-23
US20070254373A1 (en) 2007-11-01
EP2317318A1 (en) 2011-05-04
CA2522060A1 (en) 2004-10-28
AU2011201031A1 (en) 2011-04-14
EP1616186A2 (en) 2006-01-18
EP1616186A4 (en) 2007-06-06
US8101364B2 (en) 2012-01-24

Similar Documents

Publication Publication Date Title
CA2522060C (en) Fragments of fluorescent proteins for protein fragment complementation assays
Tsien Building and breeding molecules to spy on cells and tumors
US7906636B2 (en) Monomeric and dimeric fluorescent protein variants and methods for making same
US7157566B2 (en) Monomeric and dimeric fluorescent protein variants and methods for making same
DE69928255T2 (de) Biolumineszentes resonanz-energie-transfersystem (bret) und seine anwendung
US20030186229A1 (en) Emission ratiometric indicators of phosphorylation
US8669074B2 (en) Chimeric phosphorylation indicator
US7005511B2 (en) Fluorescent protein variants and methods for making same
US20030044847A1 (en) Methods for anlyzing interactions between proteins in live and intact cells
JP2004187544A (ja) Ｆｒｅｔを利用した蛍光指示薬
CA2542860A1 (en) Fluorescence indicator utilizing fret
CN101755047A (zh) 荧光蛋白及其应用方法
JP2005527210A (ja) 薬物スクリーニングのためのトランスロケーション依存的な相補性
WO2008094316A2 (en) Novel branchiostoma derived fluorescent proteins
JP4427671B2 (ja) 蛋白質のプロセッシングを測定するためのモニター蛋白質
US9400249B2 (en) Detection of biopolymer interactions, cancer cells, and pathogens using split-supercharged GFP
CA2483144A1 (en) Translocation dependent complementation for drug screening
Nguyen Fluorescent protein resonance energy transfer for high-throughput screening
Cleveland Synthetic Control of Protein Activity through Reconstitution and Fragmentation
Ghosh Designing and construction of a mammalian expression cassette containing monomeric green fluorescence protein gene in pCDNA3. 1 by molecular cloning method
Eason A GFP-based sensor to detect transiently expressed proteins
EP1784753A2 (en) Analyte sensors and method for constructing analyte binding motifs
WO2004013178A1 (en) Fusion proteins between a fluorescent protein and an ionotropic receptor and uses thereof
Metterlein et al. ChromoTek GmbH, Am Klopferspitz 19, 82152 Planegg-Martinried, Germany
CA2541920A1 (en) A bioluminescence resonance energy transfer (bret) system and its use

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150409